SCHEMBL860042

SCHEMBL860042

Cc1noc(-c2cccc(O)c2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.56
MAPT P10636 2/20 0.56
ACHE P22303 1/20 0.50
HSD17B1 P14061 7/20 0.47
HSD17B2 P37059 7/20 0.47
PDK2 Q15119 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 2/20 0.45
PARP1 P09874 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
NR1H4 Q96RI1 1/20 0.43
GRM5 P41594 1/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13415304 0.87 TP53 (0.64) TP53MAPTACHEPDK2NPC1
SCHEMBL12494 0.82 RAB9A (0.64) TP53MAPTACHENPC1RAB9A
SCHEMBL29889817 0.82 ACHE (0.52) TP53MAPTACHEPDK2NPC1
SCHEMBL12643444 0.81 NR1H4 (0.53) TP53MAPTHSD17B1HSD17B2NPC1
SCHEMBL16579451 0.81 TP53 (0.70) TP53MAPTACHENPC1RAB9A
SCHEMBL13167092 0.81 TP53 (0.70) TP53MAPTACHENPC1RAB9A
SCHEMBL2618900 0.81 TP53 (0.70) TP53MAPTACHENPC1RAB9A
SCHEMBL138239 0.81 NPC1 (0.59) TP53MAPTACHEPDK2NPC1
SCHEMBL61991 0.79 ACHE (0.64) TP53MAPTACHEPDK2NPC1
SCHEMBL2309332 0.79 TP53 (0.56) TP53MAPTACHEPDK2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119528905-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2025-02-28 CN disclosed
US-9149465-B2 Isoxazolines as inhibitors of fatty acid amide hydrolase INFINITY PHARMACEUTICALS, INC. (US) 2015-10-06 US disclosed
WO-2014027053-A1 BENZIMIDAZOLES FOR THE TREATMENT OF CANCER MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2014-02-20 WO disclosed
EP-2432771-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE Infinity Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
EP-2311830-A1 Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists AstraZeneca AB (SE) 2011-04-20 EP disclosed
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2011-02-03 US disclosed
WO-2010135360-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE INFINITY PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028478-A1 ISOXAZOLINES AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE FAAH, FAAH2, HRH2 TP53 4743/4885MAPT 3803/4885ACHE 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.